VANCOUVER, British Columbia–(BUSINESS WIRE)–May 3, 2019–

Contextual Genomics announced today that Sue Paish will become the new Chair of the Company’s Board of Directors effective May 1, 2019. Ms. Paish joined the Company’s Board of Directors in 2018 and is the former President and CEO of LifeLabs Medical Laboratory Services. Mr. Chris Wagner will be stepping down from his role as Chair, however he will remain as a Director.

Ms. Paish brings over two decades of growth-focused executive experience across multiple industries to this role. During her tenure at LifeLabs, the company grew to become Canada’s largest community laboratory and leading diagnostic testing provider. She is currently the CEO of the Digital Technology Supercluster, Chair of the Board of Directors of the Business Council of British Columbia and a director of CORIX Group. Prior to her role as CEO of LifeLabs, Ms. Paish was CEO of Pharmasave and Managing Partner of Fasken, a leading Canadian law firm.

“Sue’s proven experience in strategic growth within the healthcare industry will aid Contextual Genomics as we continue to advance our portfolio of end-to-end assays and informatics solutions for cancer testing designed for rapid deployment into labs” said Michael Ball, Contextual Genomics’ Chief Executive Officer. “Sue’s business acumen and knowledge of the diagnostics market will benefit Contextual Genomics’ efforts to enable our partner laboratories to provide access to high quality and affordable genomic testing worldwide.”`

“As a member of the Contextual Genomics’ Board for the past year, it’s been a pleasure working with the Company to expand its strategic laboratory partnerships globally” says Ms. Paish. “The momentum we are seeing around early access to FOLLOW IT, our ctDNA cancer test, will continue to expand our commercial adoption and ultimately move us towards our mission to positively impact cancer treatment.”

About Contextual Genomics (www.contextualgenomics.com):

Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide cancer treatment decisions. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools will allow Contextual Genomics to improve patient care through improved clinical trial enrolment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.

About Contextual Genomics’ Products:

The FIND ITTM and FOLLOW ITTM cancer panels are multiplex, next- generation sequencing genomic assays designed for rapid deployment into labs around the world. Both FIND ITTM and FOLLOW ITTM evaluate the mutation status of tumour DNA (FIND ITTM for solid tumours; FOLLOW ITTM for cell-free circulating tumour DNA in plasma) at 146 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QUALITY NEXUSTM is a quality control system embedded into all FIND ITTM and FOLLOW ITTM assays and into Contextual Genomics’ cloud-based analysis engine. FIND ITTM and FOLLOW ITTM physician reports provide clear information on test interpretation and linkages to current therapeutic options.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contextual Genomics
Aubree Hoover
Email: media@contextualgenomics.com